The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010).
Authors
Bliss, JKernaghan, S
Fribbens, C
Stevenson, L
Morden, J
Snowdon, C
Macpherson, I
Wardley, Andrew M
Roylance, R
Baird, R
Affiliation
The Institute of Cancer Research Clinical Trials & Statistics Unit (ICR-CTSU)Issue Date
2017